Skip to main content
Fig. 3 | BMC Pharmacology and Toxicology

Fig. 3

From: Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participants

Fig. 3

Mean serum drug concentration-time profiles (logarithmic scale) by anti-drug antibody titer in Study 1 and Study 2. (A) Study 1, FKB327; (B) Study 1, RP; (C) Study 2, FKB327; (D) Study 2, RP. ADA, anti-drug antibody. Titer subgroups: Low ADA activity (titer value of ≤25th percentile), Moderate ADA activity (titer value between 25th and 75th percentile), and High ADA activity (titer value of ≥75th percentile) at the last sampling time point

Back to article page